Your browser is no longer supported. Please, upgrade your browser.
Settings
THOR Synthorx, Inc. daily Stock Chart
THOR [NASD]
Synthorx, Inc.
Index- P/E- EPS (ttm)-1.01 Insider Own18.10% Shs Outstand30.54M Perf Week-2.97%
Market Cap569.27M Forward P/E- EPS next Y-1.64 Insider Trans- Shs Float27.35M Perf Month-11.03%
Income-30.60M PEG- EPS next Q-0.31 Inst Own90.10% Short Float1.06% Perf Quarter33.14%
Sales- P/S- EPS this Y80.40% Inst Trans- Short Ratio1.91 Perf Half Y-
Book/sh23.28 P/B0.80 EPS next Y-20.90% ROA- Target Price29.33 Perf Year-
Cash/sh0.67 P/C27.63 EPS next 5Y- ROE- 52W Range11.00 - 23.53 Perf YTD7.25%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.77% Beta-
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin- 52W Low69.45% ATR1.82
Employees25 Current Ratio0.80 Sales Q/Q- Oper. Margin- RSI (14)50.38 Volatility9.79% 9.71%
OptionableNo Debt/Eq- EPS Q/Q-935.10% Profit Margin- Rel Volume0.42 Prev Close20.15
ShortableYes LT Debt/Eq- EarningsMar 28 AMC Payout- Avg Volume151.40K Price18.64
Recom1.70 SMA20-2.54% SMA509.82% SMA20014.07% Volume64,150 Change-7.49%
Jan-02-19Initiated Jefferies Buy $21
Jan-02-19Initiated H.C. Wainwright Buy $30
Mar-19-19 08:00AM  Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-12-19 05:38PM  Synthorx: 4Q Earnings Snapshot Associated Press
04:05PM  Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
08:00AM  Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy GlobeNewswire
Feb-25-19 12:41PM  Small Cap Winners And Losers From Last Week Benzinga
Feb-21-19 04:05PM  Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -9.89%
Dec-20-18 08:00AM  Synthorx Appoints Andrew Powell, J.D., to its Board of Directors GlobeNewswire
Dec-12-18 04:05PM  Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +9.73%
Dec-06-18 09:15PM  Synthorx Announces Pricing of Initial Public Offering GlobeNewswire
04:00PM  Stocks pare losses, Nasdaq closes in the green Yahoo Finance
Dec-02-18 05:01PM  IPO Outlook For The Week: Proteins, Fashion And Finance Benzinga
Synthorx, Inc., a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.